Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
P/E ratio for Invitae Corporation (NVTA)
P/E ratio as of 2022: -0.14
According to Invitae Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.14. At the end of 2021 the company had a P/E ratio of -8.50.
P/E ratio history for Invitae Corporation from 2012 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -0.14 |
| 2021 | -8.50 |
| 2020 | -9.24 |
| 2019 | -6.06 |
| 2018 | -5.71 |
| 2017 | -3.42 |
| 2016 | -2.63 |
| 2015 | -2.58 |
| 2014 | -10.66 |
| 2013 | -10.21 |
| 2012 | -29.49 |